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Abstract 
Translating human Adipose-derived Stem Cells (hASCs) to Clinical 
Practice requires standardization of isolation and culture protocols 
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Adipose-derived stromal/stem cells (ASCs) have been explored in recent pre-clinical 
trials to treat diseases in a broad range of tissues. The ultimate goal is to translate these 
findings to clinical trials to test safety and efficacy in human subjects. However, multiple 
steps are needed to make ASC clinically  available: adipose tissue must be stable for up 
to 24 hrs during transit to cGMP laboratories1 for further processing. Second, isolation 
and expansion protocols must eliminate exposure to animal proteins2. This will require 
the development of animal-free products suitable for the culturing of the cells.  Current 
protocols3,4 employ several animal-derived reagents, such as collagenase for the 
enzymatic digestion of adipose tissue, FBS for cell culture and expansion, trypsin 
derived from porcine tissue (stomach) for cell detaching and passaging, etc.  Likewise, 
the length of time between adipose tissue harvest and processing will need to be 
systematically evaluated with respect to cell yield, viability, and function. 
The current study explores these technical challenges exploring alternative, non-animal 
sources of collagenase and trypsin-like enzymes for the isolation and passage of ASCs 
and assessing the effect of time delays on the yield and function of ASCs after 
collagenase digestion. The results obtained demonstrated that it’s possible to use 
purified or animal-free enzymes for digestion of adipose tissue without decreasing the 
yield of stromal/stem cells nor affecting their surface markers5 and differentiation 
potential. Cell yield and viability prove to be similar amongst any of the products (for 
both SVF and ASCs). The differentiation potential was not affected and ASCs were 
easily induced to adipogenic, osteogenic and chondrogenic lineages. Cell surface 
markers analysis showed no significant differences amongst any of the different grades 
of collagenase and trypsin-like products. 
These outcomes have practical implications with respect to the development of 
Standard Operating Procedures for cGMP manufacture of clinical grade human ASCs, 
which are essential for allowing their future use in the clinical practice. 
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